Myriad Genetics Adds Folate Receptor Alpha To Precise Oncology Solutions Portfolio To Expand Treatment Options For Women Living With Ovarian Cancer
Portfolio Pulse from Happy Mohamed
Myriad Genetics has added Folate Receptor Alpha (FRα) to its Precise Oncology Solutions portfolio, providing another companion diagnostic option for ovarian cancer patients. FRα establishes eligibility for FDA-approved drug ELAHERE, which is indicated for FRα-positive patients resistant to platinum-based chemotherapy.
May 24, 2023 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics has expanded its Precise Oncology Solutions portfolio with the addition of Folate Receptor Alpha, providing another companion diagnostic option for ovarian cancer patients.
The addition of Folate Receptor Alpha to Myriad Genetics' Precise Oncology Solutions portfolio expands the company's offerings and provides another companion diagnostic option for ovarian cancer patients. This could potentially lead to increased demand for Myriad Genetics' services and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100